Shattuck Labs Announces Participation in Upcoming January Investor Conferences
06 January 2022 - 12:30AM
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology
company pioneering the development of bi-functional fusion proteins
as a new class of biologic medicine for the treatment of patients
with cancer and autoimmune disease with three ongoing Phase 1
clinical trials, today announced that company management will
participate in two virtual investor conferences in January
2022.
Presentation Details
Conference: H.C. Wainwright BioConnect 2022 ConferenceFormat:
Corporate PresentationPresenter: Taylor Schreiber, M.D., Ph.D.,
Shattuck’s Chief Executive OfficerDate: January 10, 2022Time: 7:00
a.m. EST
Conference: 40th Annual J.P. Morgan Healthcare ConferenceFormat:
Corporate PresentationPresenter: Taylor Schreiber, M.D., Ph.D.,
Shattuck’s Chief Executive OfficerDate: January 13, 2022Time: 11:15
a.m. EST
A live webcast of both presentations will be available on the
Events & Presentations section of the Company’s website. A
replay of the webcasts will be archived for up to 90 days following
the presentation date.
About Shattuck Labs, Inc.Shattuck Labs,
Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company
pioneering the development of bi-functional fusion proteins as a
new class of biologic medicine for the treatment of patients with
cancer and autoimmune disease. Compounds derived from Shattuck’s
proprietary Agonist Redirected Checkpoint, ARC®, platform
simultaneously inhibit checkpoint molecules and activate
costimulatory molecules within a single therapeutic. The company’s
SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the
CD47 immune checkpoint and simultaneously agonize the CD40 pathway,
is being evaluated in two Phase 1 trials. A second product
candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase
1 trial in solid tumors or lymphomas. Additionally, the company is
advancing a proprietary Gamma Delta T Cell Engager, GADLEN™,
platform, which is designed to bridge gamma delta T cells to tumor
antigens for the treatment of patients with cancer. Shattuck has
offices in both Austin, Texas and Durham, North
Carolina. For more information, please
visit: www.ShattuckLabs.com.
Investor Contact: Conor RichardsonSenior
Director, Finance & Investor RelationsShattuck Labs,
Inc.InvestorRelations@shattucklabs.com
Media Contact:Stephanie Ascher Managing
DirectorStern Investor Relations,
Inc.Stephanie.ascher@sternir.com
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jul 2023 to Jul 2024